All In Biotech

Drug Trial Radar · NCT06521567

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

83

Planned (sponsor's estimate)

Start

Mar 6, 2025

Primary completion

Oct 13, 2026

Study completion Oct 13, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants

Conditions

  • Melanoma
  • Hodgkin Lymphoma
  • High and Low Grade Glioma
  • Glioblastoma Multiforme (GBM)
  • Diffuse Intrinsic Pontine Glioma (DIPG)
  • Ependymoma
  • Osteosarcoma
  • Hepatic Tumors
  • Hepatoblastoma
  • Hepatocellular Carcinoma (HCC)
  • Fibrolamellar Carcinoma
  • Rhabdomyosarcoma

Interventions

  • CobolimabDrug

    Cobolimab will be administered

  • DostarlimabDrug

    Dostarlimab will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1- Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 42 days
  2. Part 1- Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs) and adverse events (AEs) leading to discontinuation occurring during the studyTime frame: Up to approximately 46 months
  3. Part 1- Serum concentration of CobolimabTime frame: 1±0.5 hours (h) post-dose on Cycle 1 Day 1; 168±12 h post-dose Cycle 1Day 8; Pre-dose and 1±0.5 h post-dose on Cycle 2 Day 1; Cycle 4 Day 1 and Cycle 6 Day 1(Each cycle is of 21 days)
  4. Part 1- Serum concentration of DostarlimabTime frame: 1±0.5 h post start of cobolimab infusion on Cycle 1 Day 1; Pre-dose on Cycle 2 Day 1; Cycle 4 Day 1 and Cycle 6 Day 1(Each cycle is of 21 days)
  5. Part 1- Recommended Phase 2 Dose (RP2D) of Cobolimab and Dostarlimab combinationTime frame: Up to approximately 12 months
  6. Part 2- Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 46 months
  7. Part 2- Number of participants with TEAEs, SAEs, imAEs, TEAEs leading to death and AEs leading to discontinuationTime frame: Up to approximately 46 months
  8. Part 2-Number of participants with changes in laboratory parameters, vital signs and cardiac parametersTime frame: Up to approximately 46 months

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Hackensack, New Jersey

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Providence, Rhode Island

  • GSK Investigational Site

    Madison, Wisconsin

  • GSK Investigational Site

    Brno, Czechia

  • GSK Investigational Site

    Phaha 5, Czechia

  • GSK Investigational Site

    Copenhagen, Denmark

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Strasbourg, France

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Bologna, Italy

  • GSK Investigational Site

    Naples, Italy

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.